Abstract: The present disclosure is directed to an SR-B1-targeting nanomicelle and compositions, methods of synthesis and methods of use thereof. The nanomicelle may be an HDL-mimetic drug delivery system and may be cross-linked with DSS. The composition may contain a therapeutic agent with the ability to treat cancers, especially sarcomas.

Abstract: The present invention provides high density lipoprotein (HDL) or reconstituted HDL (rHDL) particles for the delivery of non-nucleic acid therapeutic agents, therapeutic agents or nucleic acids to cells and tissues. The use of HDL or rHDL particles has advantages over other delivery systems because they are smaller in size and their contents are rapidly internalized by receptors of specific cells, including receptors on the surface of tumor tissue. The HDL or rHDL nanoparticles of the present invention may include a positively charged polyamino acid, which neutralizes the negatively charged nucleic acid, thus allowing for successful incorporation of the nucleic acid into an HDL or rHDL particle. Methods of delivering therapeutic agents to cells and target tissues using the disclosed HDL or rHDL particles are provided as are methods of treating various diseases and disorders.

Abstract: The invention provide herein provides for a targeted drug delivery vehicle compositions, methods of manufacture, and methods of treatment for therapeutic applications.

Abstract: The present disclosure provides targeted drug delivery vehicle compositions comprising a drug composition and targeted poly-amino-acid subunits, methods of manufacture, and methods of treatment for numerous diseases.